Not FDA-approved
Bones & muscles
IGF-1 LR3
Evidence
Limited human data
Class
Long-acting IGF-1 variant
KEY TAKEAWAY
IGF-1 LR3 is a modified IGF-1 with a 13-amino-acid extension and a substitution at position 3. It is used mainly in cell culture and is sold online for performance use. IGF-1 LR3 is not FDA-approved. Mecasermin (Increlex) is the approved IGF-1 product.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting IGF-1 variant
Main uses
Used in cell culture; sold online for muscle growth
Key fact
IGF-1 LR3 is not FDA-approved. Mecasermin (Increlex) is the approved IGF-1 product.
Route
Injected when used outside the lab
Evidence strength
Limited human data
IGF-1 LR3 is a modified IGF-1 with a 13-amino-acid extension and a substitution at position 3. It is used mainly in cell culture and is sold online for performance use.
The changes reduce binding to IGF-binding proteins, so it stays active longer and is more potent than natural IGF-1.
IGF-1 LR3 is not FDA-approved. Mecasermin (Increlex) is the approved IGF-1 product.
Used in cell culture; sold online for muscle growth.
Low blood sugar and unwanted tissue growth are concerns. Human safety data do not exist.
IGF-1 LR3: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.